Interleukin 1beta levels in patients with reactive arthritis

Yavuz BAYKAL, Bekir ÇAKIR, Zafer ÇALIŞKANER, Tahir ÜNAL, Arif YÖNEM, Fikri KOCABALKAN, Ali ŞENGÜL, Kenan SAĞLAM

Özet

Bu caltsma reaktif artritli hastalarda serum interlokin 1-fi (IL-lp) duzeylerini olcmek ve biinun hastaligm aktivitesi He ilskisini degerlendirmek amaciyla yapilmistir. gahsma 31 reaktif artritli ve 21 saghkh kontrol vakasi He yapilmi§tir. Qahsmada reaktif artritli hastalartn serum IL-lfi diizeyleri kontrol grubuna oranla daha yiiksek bulunmus olmasma ragmen, bu farkhhk istatistiksel acidan anlamh bulunmamistir. Ayrtca serum IL-lfi diizeyleri, akut faz cevabi gostergeleri olan sedimentasyon ve C- reaktif protein He de iliskili bulunmamistir. Sonug olarak, serum IL-lfi duzeylerinin reaktif artritli hastalarda hastahgin aktivitesini gosterecek sekilde artmadigmi ortaya koyduk. Dolayisiyla serum IL-lfi olgilmu reaktif artritli hastalarda hastahk aktivitesini belirlemede yararh bir gosterge degildir.

Abstract

This study was performed to determine serum interleukin 1-fi (IL-l[i) levels and to investigate its relationship with disease activity in patients with reactive arthritis. Thirty-one reactive arthritis patients and 21 healthy control subjects were enrolled into the study. Although serum IL-lfi levels were found to be higher in patient group when compared to those of control group, this difference was not statistically significant. Furthermore, serum IL-lfi levels showed no relationship with erythrocyte sedimentation rate and C-reactive protein, which are markers of acute phase response. In conclusion, serum IL-lfi levels do not increase to establish the disease activity in patients with reactive arthritis. Therefore, serum IL-lfi levels are not useful to evaluate the disease activity in such cases.